Key Highlights
- 0.154% is the gap at Loews (NYSE:L), with the 50-day average of USD 108.88 under the 200-day of USD 109.05, per published market data on October 16, 2026 intraday. The USD 109.73 price is 0.6% above the 200-day, the only name of four above its long average.
- 0.171% is the gap at Baker Hughes (NASDAQ:BKR), with the 50-day average of USD 59.80 under the 200-day of USD 59.90. The USD 55.83 price is 6.8% below the 200-day, own arithmetic, after 2026 revenue guidance rose to USD 28.50 billion to USD 30.30 billion.
- 0.193% is the gap at BridgeBio Pharma (NASDAQ:BBIO), with the 50-day average of USD 72.94 under the 200-day of USD 73.08. The USD 66.07 price is 9.6% below the 200-day and 29.3% below the 52-week high, own arithmetic, with an FDA decision due November 27, 2026.
- 0.629% is the gap at Broadcom (NASDAQ:AVGO), the widest of four, with the 50-day average of USD 365.92 under the 200-day of USD 368.24. The USD 338.50 quote is 8.1% below the 200-day, own arithmetic, after a reported USD 42 billion customer financing plan.
Loews (NYSE:L)
The mildest cross of the four is the one where the price still sits above both averages. Second quarter EPS was USD 2.16 against USD 1.87, up 15.5% on own arithmetic, per the company release dated August 3, 2026. Boardwalk Pipelines earned USD 100 million against USD 88 million and Loews Hotels earned USD 48 million against USD 28 million, while CNA Financial core income eased to USD 324 million from USD 335 million as the combined ratio rose to 96.5% from 94.1%. The parent held USD 4.4 billion of cash and investments against USD 1.8 billion of debt at June 30, 2026. The stock trades at 13.4 times trailing EPS of USD 8.16 and 1.17 times book value, own arithmetic. What separates Loews from the other three: no company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026, so the cross reflects drift, not news. The so-what: the November 2, 2026 report tests the CNA combined ratio.
Baker Hughes (NASDAQ:BKR)
Guidance went up while the chart went down, which is the tension. On September 9, 2026 the company lifted 2026 revenue guidance after closing the USD 13.6 billion Chart Industries acquisition on July 16, 2026. The USD 29.40 billion midpoint is 3.8% above the USD 28.31 billion consensus compiled before the update, own arithmetic. Remaining performance obligations were USD 40.1 billion at June 30, with orders of USD 10.5 billion and a book-to-bill of 1.6. Management expects Chart to deliver 55% to 65% of its segment core profit in the fourth quarter, so earnings skew to year-end. Shares closed at USD 54.40 on October 15 against a 52-week range of USD 44.22 to USD 70.41. What separates Baker Hughes from the other three: it is the oil and gas name, and the stock fell 5.5% on May 27, 2026 when crude dropped on peace deal progress. The so-what: the report after the close on October 27, 2026 tests Chart margins, and UBS cut its target to USD 69 from USD 72, with BofA at USD 73 from USD 74. Goldman Sachs reinstated coverage with a Buy rating on September 30, 2026.
BridgeBio Pharma (NASDAQ:BBIO)
The market is weighing a revenue ramp against a binary regulatory event. Attruby net product revenue was USD 222.4 million in the second quarter against USD 71.5 million a year earlier, and total revenue was USD 243.7 million, up 120%. The operating loss narrowed to USD 107.1 million from USD 134.3 million. Cash of USD 720.2 million plus the USD 1 billion Sixth Street preferred equity that closed July 1, 2026 gives pro forma liquidity of USD 1,720.2 million, own arithmetic, though conversion terms were not reviewed. The stock is down 12.67% year to date, and short interest is 11.73% of float with 5.85 days to cover. What separates BridgeBio from the other three: it is the only one where a single regulator date, November 27, 2026 for BBP-418, can move the price more than any average. The so-what: no single October catalyst was identified, and the report is estimated for October 28. Third quarter consensus is revenue of USD 281.1 million and EPS of negative USD 0.57, per published market data. UBS assumed coverage at Buy with a USD 92 target.
Broadcom (NASDAQ:AVGO)
A 0.629% gap is the widest of the four, yet the fundamentals read like the strongest. Fiscal third quarter revenue was USD 29.6 billion, up 86%, with a 67.9% operating margin and USD 13.7 billion of free cash flow, own arithmetic on company figures. AI semiconductor revenue was USD 16.7 billion, up 221%. Fourth quarter guidance is revenue of USD 34.8 billion with a gross margin of 73%, down from 75%. The shares fell 6.9% from USD 362.51 on October 5, 2026 to USD 337.52 on October 16, simple arithmetic on two published prices, and intraday data also show USD 338.50, the figure used for the gap. A reported plan to lend Anthropic up to USD 42 billion to lease chips was not confirmed in company material. What separates Broadcom from the other three: it is the semiconductor name, valued at 46.30 times trailing earnings. The so-what: the fiscal fourth quarter report has not been dated by the company, and December is typical. Evercore at USD 578 and BNP Paribas Exane at USD 715 held constructive targets in September, which are opinions.
Where Things Stand
BridgeBio Pharma (NASDAQ:BBIO) sits deepest, 9.6% below its 200-day average, ahead of Broadcom at 8.1% and Baker Hughes at 6.8%, own arithmetic on published data. Loews (NYSE:L) is 0.6% above. By gap, Broadcom (NASDAQ:AVGO) is widest at 0.629%, a USD 2.32 difference, while the other three fall between 0.154% and 0.193%. Baker Hughes (NASDAQ:BKR) reports October 27 after the close, BridgeBio is estimated for October 28, Loews reports November 2 and BridgeBio faces the FDA on November 27, 2026. Broadcom has no company-confirmed date, and a crossover is not a forecast. This article is not investment advice.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...